Biodexa Pharmaceuticals (BDRX) Income from Discontinued Operations (2016 - 2019)

Biodexa Pharmaceuticals has disclosed Income from Discontinued Operations across 4 years of filings, most recently posting -$1.2 million for Q4 2019.

• In Q4 2019, Income from Discontinued Operations rose 79.7% year-over-year to -$1.2 million; the TTM figure through Dec 2019 stood at -$39.0 million (changed N/A YoY), while the FY2019 annual figure was -$1.2 million, up 80.58% from the prior year.
• Income from Discontinued Operations came in at -$1.2 million for Q4 2019 at Biodexa Pharmaceuticals, up from -$6.0 million in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of -$1.2 million in Q4 2019 to a low of -$26.0 million in Q4 2016.
• Average Income from Discontinued Operations over 4 years is -$9.8 million, with a median of -$5.9 million recorded in 2018.
• Year-over-year, Income from Discontinued Operations slipped 3.66% in 2018 and soared 79.7% in 2019.
• Over 4 years, Income from Discontinued Operations stood at -$26.0 million in 2016, then soared by 77.76% to -$5.8 million in 2017, then slipped by 3.66% to -$6.0 million in 2018, then jumped by 79.7% to -$1.2 million in 2019.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were -$1.2 million in Q4 2019, -$6.0 million in Q4 2018, and -$5.8 million in Q4 2017.